STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTLA
  4. [Form 4] Intellia Therapeutics, Inc. Insider Trading Activity

Intellia Therapeutics (NTLA) CEO sells shares around $13

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) reported that President and CEO John M. Leonard sold shares of Common Stock in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On August 20, 2026, he sold 19,890 shares at a weighted average price of $12.60 per share, in multiple trades between $12.32 and $13.00. On August 21, 2026, he sold an additional 2,785 shares at $13.00 per share. The filing also notes 58,415 shares of common stock held indirectly by the John M. Leonard 2015 Irrevocable Trust.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider LEONARD JOHN M
Role President and CEO
Sold 22,675 shs ($287K)
Type Security Shares Price Value
Sale Common Stock F1 2,785 $13.00 $36K
Sale Common Stock F1, F2 19,890 $12.60 $251K
holding Common Stock F3 -- -- --
Holdings After Transaction: Common Stock — 1,147,064 shares (Direct); Common Stock — 58,415 shares (Indirect, By Trust)
Footnotes (3)
  1. F1. The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
  3. F3. Shares held by the John M. Leonard 2015 Irrevocable Trust.
Shares sold on August 20, 2026 19,890 shares of Common Stock Open-market or private sale by John M. Leonard
Weighted average sale price on August 20, 2026 $12.60 per share Multiple transactions between $12.32 and $13.00
Price range on August 20, 2026 sales $12.32 to $13.00 per share Range for multiple sale transactions
Shares sold on August 21, 2026 2,785 shares of Common Stock Open-market or private sale by John M. Leonard
Sale price on August 21, 2026 $13.00 per share Single reported price for that day’s sale
Total reported shares sold 22,675 shares of Common Stock Sum of August 20 and 21, 2026 sales
Indirect shares held by trust 58,415 shares of Common Stock Held by the John M. Leonard 2015 Irrevocable Trust
Rule 10b5-1 trading plan adoption date May 21, 2026 Plan under which the reported sales occurred automatically
Rule 10b5-1 trading plan regulatory
"occurred automatically pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Irrevocable Trust financial
"Shares held by the John M. Leonard 2015 Irrevocable Trust."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

FAQ

What insider transactions did NTLA report for John M. Leonard on this Form 4?
John M. Leonard reported two sales of Intellia Therapeutics (NTLA) common stock totaling 22,675 shares on August 20–21, 2026, plus an updated indirect holding of shares in a trust.

How many NTLA shares did John M. Leonard sell on August 20, 2026?
On August 20, 2026, John M. Leonard sold 19,890 shares of Intellia Therapeutics (NTLA) common stock at a weighted average price of $12.60 per share, in multiple trades priced between $12.32 and $13.00.

At what price did John M. Leonard sell NTLA shares on August 21, 2026?
On August 21, 2026, John M. Leonard sold 2,785 shares of Intellia Therapeutics (NTLA) common stock at $13.00 per share in an open-market or private transaction.

Were the reported NTLA share sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales occurred automatically under a Rule 10b5-1 trading plan adopted by John M. Leonard on May 21, 2026.

How many NTLA shares are reported as held indirectly by trust for John M. Leonard?
The Form 4 reports 58,415 shares of Intellia Therapeutics (NTLA) common stock held indirectly, described as shares held by the John M. Leonard 2015 Irrevocable Trust.

Does the filing disclose John M. Leonard’s total direct NTLA share ownership after these sales?
The filing provides the shares sold and the trust’s 58,415-share position, but it does not state an explicit total direct share count following the reported transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEONARD JOHN M
(Last)(First)(Middle)
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
(Street)
CAMBRIDGE MASSACHUSETTS 02139
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/20/2026S(1)19,890D$12.6(2)1,149,849D
Common Stock08/21/2026S(1)2,785D$131,147,064D
Common Stock58,415(3)IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
3. Shares held by the John M. Leonard 2015 Irrevocable Trust.
/s/ James Basta, attorney-in-fact08/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR